In previous clinical studies for pegylated G-CSF conducted in Japan, bone pain was found in 6.4% of treated patients with breast cancer (vs. 2.3% in the placebo group) and back pain in 19.1% of treated patients (vs. 15.0%) [8]. Here, CSF3 is linked to breast cancer.